| 摘要 |
<p>The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R<SUB>1-6 </SUB>are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.</p> |
